Pain End of treatment and long term · men and women aged over 18 years with chronic fatigue syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physical functioning End of treatment and long term · men and women aged over 18 years with chronic fatigue syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · men and women aged over 18 years with chronic fatigue syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sleep · men and women aged over 18 years with chronic fatigue syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy for ADHD symptoms (parents using a rating scale) ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Efficacy for ADHD symptoms (teachers using a rating scale) ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
CGI (response rate) ‐ desipramine and nortriptyline · Children and adolescents with ADHD
Tricyclic antidepressants (TCAs) may leads to higher CGI (response rate) ‐ desipramine and nortriptyline compared with placebo (low certainty).
1 finding from 1 review
All‐cause treatment discontinuation ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Cognition at end of treatment · people with stroke
1 finding from 1 review
Activities of daily living · people with stroke
1 finding from 1 review
Disability: mean scores at end of treatment (Analysis 1.10) · people with stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (Analysis 1.14) · people with stroke
It is very uncertain whether pharmacological interventions (antidepressants) changes adverse events: death ‐ at end of treatment Analysis 1.12 compared with placebo (very low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, end of intervention · adults who withdraw from chronic benzodiazepine use
It is very uncertain whether tricyclic antidepressants changes benzodiazepine discontinuation, end of intervention compared with placebo (very low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
Tricyclic antidepressants may leads to higher benzodiazepine discontinuation, longest compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (VAS‐Pain, SCL‐90‐R Somatisation Subscore) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
Tricyclic antidepressants showed no clear difference in acceptability (all‐cause drop‐outs4) compared with another medication (low certainty).
1 finding from 1 review